It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.
A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.
The committee spoke out against clinical applications of human germline genome editing and called for stronger global governance of the field.
The deal gives Alexion rights to an anti-FcRn drug designed to have a longer half-life than rival assets in development at Argenx and UCB.
Merck is extending its 2015 R&D pact with NGM Bio for a broad range of early-stage assets. It's also culling one therapy that didn't work out.
The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.
Phase 1 data for PhaseBio's Brilinta reversal agent showed the drug quickly reversed the effects of Brilinta without causing serious side effects.
The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics.
University of Wisconsin researchers have found an enzyme that acts as a key regulator of p53, which they believe may inspire cancer treatments ideas.
Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.
